Nektar Therapeutics: UBS initiates coverage with neutral rating and $53 target price
NKTR•UBS initiated coverage of Nektar Therapeutics with a neutral rating and a $53 target price.
Related News
Vylor Inc.: UBS initiates coverage with buy rating and $89 target price
VYLR•
Low-sulphur gasoil deliveries for October fall at expiry
USO•
Bristol Myers radiopharma cancer drug slows rare tumor progression in study
BMY•
Nasdaq trade halt continues; volatility trading pause at 9:53 a.m.
NXGL•
Nasdaq trade halt: volatility trading pause at 9:58 a.m.
RIBBU•